Table 2.

Patient disposition.

	CD [n = 88]	UC [n = 79]	Total [n = 167]
Completed XAP-PK sub-study to Week 56, n [%]	80 [90.9]	73 [92.4]	153 [91.6]
Remained on Q8W dosing to Week 56, n [%]	76 [86.4]	71 [89.9]	147 [88.0]
Changed dosing from Q8W to Q4W, n [%]	4 [4.5]a	2 [2.5]	6 [3.6]
Completed main study before Week 56b	1 [1.1]	2 [2.5]	3 [1.8]
Premature discontinuation, n [%]	7 [8.0]	4 [5.1]	11 [6.6]
Voluntary withdrawal	4 [4.5]	3 [3.8]	7 [4.2]
No longer adequate benefit	2 [2.3]	0	2 [1.2]
Lost to follow-up	0	1 [1.3]	1 [0.6]
Pregnancy	1 [1.1]	0	1 [0.6]

CD, Crohn’s disease; PK, pharmacokinetic; Q4W, every 4 weeks; Q8W, every 8 weeks; UC, ulcerative colitis; XAP, Extended Access Program.

^aOne additional patient re-escalated to Q4W dosing but prematurely discontinued the study due to loss of treatment benefit.

^bPatients discontinued the XAP study and continued treatment with commercially available vedolizumab.